Inventa is a technology company.
Inventa is a full-service B2B platform in Brazil that integrates technology, credit, and logistics to simplify operations for businesses.
Inventa has raised $25.0M across 2 funding rounds.
Inventa has raised $25.0M in total across 2 funding rounds.
Inventa has raised $25.0M in total across 2 funding rounds.
Inventa's investors include Accel, Notable Capital, Globo Ventures, monashees, Hans Tung, NXTP Ventures, Valor Capital Group, Guilherme Bonifacio, Pierpaolo Barbieri.
Inventa Technologies primarily accelerates innovation and technology development in specialty chemicals, oleochemicals, biopolymers, functional foods, and life sciences by commercializing intellectual property through expert teams and practical plant project implementations.[1][5] A separate entity focuses on medical technologies, developing solutions like the Hi-Beam Flash native Mobile Linear Accelerator for Intraoperative Radiation Therapy (IORT), high-end radiology mobile units, modular hospital buildings, and AI distribution for lung cancer screening.[2] These companies serve industrial innovators and healthcare providers, solving challenges in tech commercialization and optimized medical resource use, with operations showing steady activity as an active UK-registered firm since 2006.[4]
Inventa Technologies (UK company number 05747818) was incorporated on March 17, 2006, as a private limited company based in London, initially focusing on information technology consultancy (SIC 62020) and advertising agencies (SIC 73110).[4] Its evolution centers on practical innovation acceleration, leading to successful plant projects in chemicals and life sciences, though specific founders or key partners are not detailed in available records.[1][5] The medical-focused Inventa Technologies emerged to address healthcare branches like radiation oncology and radiology, developing proprietary tech such as Hi-Beam and modular constructions, with early expansion into AI distribution for the Italian market.[2]
Inventa rides trends in sustainable materials (biopolymers, oleochemicals) and precision medicine (radiation oncology, AI screening), where demand for rapid IP commercialization and modular healthcare infrastructure addresses supply chain bottlenecks and aging populations.[1][2][5] Timing aligns with post-pandemic pushes for mobile, efficient medical tech and green chemistry innovations, bolstered by regulatory support for life sciences and modular builds that cut hospital construction timelines.[2][4] It influences ecosystems by enabling scalable implementations, bridging R&D gaps for chemical/life science firms and enhancing oncology/radiology access in underserved areas.[1][2]
Inventa Technologies is poised to expand in green chemistry and mobile oncology solutions, capitalizing on AI integration and modular health infrastructure amid global sustainability mandates and healthcare digitization. Trends like flash radiotherapy advancements and biopolymer scaling will shape growth, potentially amplifying its niche influence through partnerships. As a steady operator since 2006, it ties back to its core strength: practical tech acceleration across chemicals and medicine, positioning it for impactful implementations ahead.[1][2][4][5]
Inventa has raised $25.0M across 2 funding rounds. Most recently, it raised $20.0M Series A in January 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2022 | $20.0M Series A | Accel, Notable Capital | |
| Oct 1, 2021 | $5.0M Seed | Globo Ventures, monashees, Hans Tung, NXTP Ventures, Valor Capital Group, Guilherme Bonifacio, Pierpaolo Barbieri |